Billionaire Druckenmiller’s 5 Stocks Picks with Huge Upside Potential

3. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Duquesne Capital’s Equity Stake: $6.94 Million
Share Price Upside Potential: 124.02%
Number of Hedge Fund Holders: 19

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a healthcare investment in Duquesne Capital’s portfolio that operates as a clinical-stage biotechnology company. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) leverages technological innovations, data science, and engineering to enhance drug discovery. It is currently working on REC 994 to treat cerebral cavernous malformation.

While Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is down by about 4% for the year, it is one of the billionaire Druckenmiller stock picks with tremendous upside potential. Analysts on Wall Street rate it as a Buy with an average price target of $16.60, implying 124.02% upside potential from current levels. Druckenmiller reduced his stock exposure in Q3 2023 by 35% to $6.9 million, accounting for 0.24% of the portfolio.

As per Insider Monkey’s database, 19 hedge funds held stakes in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in Q3 2023, compared to 15 funds in the prior quarter. Mubadala Investment’s 

MIC Capital Partners is the leading shareholder of the company, with stakes worth $64.66 million.

Follow Recursion Pharmaceuticals Inc.

[/company-follow-email]